KALARIS THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
KALARIS THERAPEUTICS, INC. (KLRS) reported Earnings Per Share, Basic and Diluted of -$0.69 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-05
- KALARIS THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.69.
- KALARIS THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.91.
- KALARIS THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.72.
- KALARIS THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.60.
- KALARIS THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$2.74.
- KALARIS THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$2.59.
- KALARIS THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$18.54.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.69 10-Q · filed 2022-05-05 | -$1.60 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$2.32 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$2.93 derived: net income ÷ weighted average shares · filed 2023-11-02 |
| 2021-12-31 | -$0.91 derived: net income ÷ weighted average shares · filed 2023-02-15 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-02-15 | -$2.24 derived: net income ÷ weighted average shares · filed 2023-02-15 | -$2.74 10-K · filed 2022-02-10 |
| 2021-09-30 | -$0.72 10-Q · filed 2021-11-05 | -$1.33 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.82 10-Q · filed 2021-11-05 | -$2.23 derived: net income ÷ weighted average shares · filed 2022-11-03 |
| 2021-06-30 | -$0.60 10-Q · filed 2021-08-06 | -$1.10 10-Q · filed 2021-08-06 | -$1.51 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$2.07 derived: net income ÷ weighted average shares · filed 2022-11-03 |
| 2021-03-31 | -$0.50 10-Q · filed 2022-05-05 | -$0.90 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.45 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$2.18 derived: net income ÷ weighted average shares · filed 2022-11-03 |
| 2020-12-31 | -$0.41 derived: net income ÷ weighted average shares · filed 2022-02-10 | -$0.95 derived: net income ÷ weighted average shares · filed 2022-02-10 | -$1.73 derived: net income ÷ weighted average shares · filed 2022-02-10 | -$2.59 10-K · filed 2022-02-10 |
| 2020-09-30 | -$0.58 10-Q · filed 2021-11-05 | -$1.64 derived: net income ÷ weighted average shares · filed 2021-11-05 | -$2.93 10-Q · filed 2021-11-05 | -$4.53 derived: net income ÷ weighted average shares · filed 2021-11-05 |
| 2020-06-30 | -$4.43 10-Q · filed 2021-08-06 | -$8.66 10-Q · filed 2021-08-06 | -$13.36 derived: net income ÷ weighted average shares · filed 2021-11-05 | -$18.18 derived: net income ÷ weighted average shares · filed 2021-11-05 |
| 2020-03-31 | -$4.21 10-Q · filed 2021-05-06 | -$8.94 derived: net income ÷ weighted average shares · filed 2021-11-05 | -$13.80 derived: net income ÷ weighted average shares · filed 2021-11-05 | -$18.69 derived: net income ÷ weighted average shares · filed 2021-11-05 |
| 2019-12-31 | -$4.78 derived: net income ÷ weighted average shares · filed 2021-02-12 | -$9.72 derived: net income ÷ weighted average shares · filed 2021-02-12 | -$14.72 derived: net income ÷ weighted average shares · filed 2021-02-12 | -$18.54 10-K · filed 2021-02-12 |
| 2019-09-30 | -$4.97 10-Q · filed 2020-11-10 | -$10.00 derived: net income ÷ weighted average shares · filed 2020-11-10 | -$13.67 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$5.05 10-Q · filed 2020-09-02 | -$8.49 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |